Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Paul Hartmann AG's Debt-to-Equity or its related term are showing as below:
FRA:PHH2'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.09 Max: 0.3
Current: 0.29
During the past 13 years, the highest Debt-to-Equity Ratio of Paul Hartmann AG was 0.30. The lowest was 0.01. And the median was 0.09.
FRA:PHH2's Debt-to-Equity is ranked worse than 56.96% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs FRA:PHH2: 0.29
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Paul Hartmann AG Debt-to-Equity Related Terms
Paul Hartmann AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Paul Hartmann AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHH2 vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG (FRA:PHH2) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Paul Hartmann AG and its competitors. Over the past decade, Paul Hartmann AG's Debt-to-Equity has ranged from 0.01 to 0.30. According to the industry distribution chart, Paul Hartmann AG ranks #397 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 57%.
Is Paul Hartmann AG's Debt-to-Equity too high?
Paul Hartmann AG's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.30. Based on the distribution chart, Paul Hartmann AG ranks #397 out of 697 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Paul Hartmann AG has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #397 out of 697 companies for Debt-to-Equity. This places Paul Hartmann AG in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Historically, Paul Hartmann AG's own Debt-to-Equity has ranged from 0.01 to 0.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Paul Hartmann AG and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (FRA:PHH2) is currently considered Modestly Undervalued. The stock's GF Value™ is €226.94, compared to a current price of €201.00 — trading 11.4% below its estimated fair value. The current Debt-to-Equity is 0.00. Paul Hartmann AG's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Paul Hartmann AG (FRA:PHH2), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (FRA:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €201.00 is trading 11.4% below its estimated GF Value™ of €226.94.
GuruFocus considers Paul Hartmann AG to be Modestly Undervalued.
Key valuation signals for FRA:PHH2:
Debt-to-Equity: 0.00
GF Value™: €226.94 vs. price of €201.00 (11.4% below fair value)
No single metric tells the full story. See the FRA:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
64GF Score
Get the complete analysis for FRA:PHH2
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHH2 has been successfully added to your 
